These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11330541)

  • 1. Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody.
    Garrity ER; Villanueva J; Bhorade SM; Husain AN; Vigneswaran WT
    Transplantation; 2001 Mar; 71(6):773-7. PubMed ID: 11330541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody.
    Beniaminovitz A; Itescu S; Lietz K; Donovan M; Burke EM; Groff BD; Edwards N; Mancini DM
    N Engl J Med; 2000 Mar; 342(9):613-9. PubMed ID: 10699160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early experience with two-dose daclizumab in the prevention of acute rejection in cardiac transplantation.
    Joyal D; Cantarovich M; Cecere R; Giannetti N
    Clin Transplant; 2004 Oct; 18(5):493-6. PubMed ID: 15344949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.
    Wiseman LR; Faulds D
    Drugs; 1999 Dec; 58(6):1029-42. PubMed ID: 10651389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.
    Nashan B; Light S; Hardie IR; Lin A; Johnson JR
    Transplantation; 1999 Jan; 67(1):110-5. PubMed ID: 9921806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation.
    Bumgardner GL; Hardie I; Johnson RW; Lin A; Nashan B; Pescovitz MD; Ramos E; Vincenti F;
    Transplantation; 2001 Sep; 72(5):839-45. PubMed ID: 11571447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation.
    Ahsan N; Holman MJ; Jarowenko MV; Razzaque MS; Yang HC
    Am J Transplant; 2002 Jul; 2(6):568-73. PubMed ID: 12118902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
    Ciancio G; Burke GW; Suzart K; Roth D; Kupin W; Rosen A; Olson L; Esquenazi V; Miller J
    Transplantation; 2002 Apr; 73(7):1100-6. PubMed ID: 11965039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.
    Vincenti F; Kirkman R; Light S; Bumgardner G; Pescovitz M; Halloran P; Neylan J; Wilkinson A; Ekberg H; Gaston R; Backman L; Burdick J
    N Engl J Med; 1998 Jan; 338(3):161-5. PubMed ID: 9428817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and antithymocyte globulin.
    Lischke R; Simonek J; Davidová R; Schützner J; Stolz AJ; Vojácek J; Burkert J; Pafko P
    Transplant Proc; 2007; 39(1):205-12. PubMed ID: 17275507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti-thymocyte globulin and daclizumab.
    Burton CM; Andersen CB; Jensen AS; Iversen M; Milman N; Boesgaard S; Arendrup H; Eliasen K; Carlsen J
    J Heart Lung Transplant; 2006 Jun; 25(6):638-47. PubMed ID: 16730569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab.
    Chin C; Pittson S; Luikart H; Bernstein D; Robbins R; Reitz B; Oyer P; Valantine H
    Transplantation; 2005 Aug; 80(4):477-81. PubMed ID: 16123721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group.
    Hengster P; Pescovitz MD; Hyatt D; Margreiter R
    Transplantation; 1999 Jul; 68(2):310-3. PubMed ID: 10440409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation.
    Ailawadi G; Smith PW; Oka T; Wang H; Kozower BD; Daniel TM; Kron IL; Jones DR
    J Thorac Cardiovasc Surg; 2008 Mar; 135(3):594-602. PubMed ID: 18329476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
    Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation.
    Lo A; Stratta RJ; Alloway RR; Egidi MF; Shokouh-Amiri MH; Grewal HP; Gaber AO
    Transplant Proc; 2001; 33(1-2):1701-3. PubMed ID: 11267477
    [No Abstract]   [Full Text] [Related]  

  • 17. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab.
    Brock MV; Borja MC; Ferber L; Orens JB; Anzcek RA; Krishnan J; Yang SC; Conte JV
    J Heart Lung Transplant; 2001 Dec; 20(12):1282-90. PubMed ID: 11744411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-year outcomes with alemtuzumab induction after lung transplantation.
    Shyu S; Dew MA; Pilewski JM; DeVito Dabbs AJ; Zaldonis DB; Studer SM; Crespo MM; Toyoda Y; Bermudez CA; McCurry KR
    J Heart Lung Transplant; 2011 Jul; 30(7):743-54. PubMed ID: 21420318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A
    Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation.
    Hirose R; Roberts JP; Quan D; Osorio RW; Freise C; Ascher NL; Stock PG
    Transplantation; 2000 Jan; 69(2):307-11. PubMed ID: 10670644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.